A clinical trial will assess a combination of MGTA-145 plus plerixafor as a new regimen for aiding in the collection of blood stem cells from adults and adolescents with sickle cell disease (SCD). The proof-of-concept trial, a collaboration between Magenta Therapeutics and Bluebird Bio, may establish this new combination as a better mobilization regimen for these patients. Such a much-needed regimen would provide an important alternative for people with SCD who cannot use more common…

You must be logged in to read/download the full post.